Timothy Pardee MD PhD

Hematologic Oncology

Associate Professor, Internal Medicine, Wake Forest University School of Medicine

1 S Hawthorne Rd# HanesWinston-Salem, NC 27157
Phone+1 336-716-5847
Fax+1 336-716-2067

Dr. Pardee is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pardee's full profile Already have an account?

Education & Training

Stony Brook Medicine/University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2009
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2003 - 2005
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NC State Medical License 2009 - 2027
NY State Medical License 2005 - 2010
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Inpatient EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017

Clinical Trials

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
COMPLETED
PHASE1
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
COMPLETED
PHASE3
Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia
COMPLETED
NA

Publications & Presentations

PubMed

2 citations
Sarcopenia in Older Adults with Hematologic Malignancies: A Comprehensive Review of Epidemiology, Prognosis, and Interventions.
Samuel J Yates, Nadine H Abdallah, Konstantinos Christofyllakis, Brandon N VanderVeen, Timothy S Pardee
Cancers. 2026-02-03
1 citations
AML Disparities Across Racial Ancestry Groups: A Spotlight on the NPM1 Mutations.
Sarvath Aafreen Sanaullah, Pierre-Alexandre Vidi, Timothy S Pardee
International Journal of Molecular Sciences. 2026-01-03
3 citations
Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.
Raphael Steiner, Liana Nikolaenko, Ranjit Nair, Venkatraman Seshan, Swetha Kambhampati Thiruvengadam
Blood Advances. 2025-11-11

Abstracts/Posters

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements o...
Timothy S. Pardee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Evaluating the Utilization of All-Trans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia
Timothy S. Pardee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Multicentre, Open Label, Randomized Phase III Study of Cpi-613¬ (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cyt...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly ActiveClinically Relevant Abstract
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613 in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology AssociationJune 16th, 2018
WFIRM Scientists Study Space Radiation Health Effects to Keep Astronauts SafeNovember 14th, 2017
Pappas Capital and Wake Forest Innovations Announce First Investments by the Catalyst FundJanuary 11th, 2017

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Similar Physicians & HCPs

Antonius Miller, MD
OncWinston-Salem, NC
Glenn Lesser, MD
OncWinston-Salem, NC
David Hurd, MD
OncWinston-Salem, NC
Timothy Collins, MD
OncWinston-Salem, NC
Mercedes Porosnicu, MD
OncWinston-Salem, NC
Heidi Klepin, MD
OncWinston-Salem, NC
Julia Lawrence, DO
OncWinston-Salem, NC
Rupali Bhave, MD
OncWinston-Salem, NC
Mihaela Vatca, MD
OncWinston-Salem, NC
Andrew Farland, MD
OncWinston-Salem, NC

Doximity / States / North Carolina / Winston-Salem / Timothy Pardee, MD

Dr. Timothy Pardee, Dr. Timothy Pardee, MD, Dr. T Pardee